MMP-2 expression associates with CA 125 and clinical course in endometrial carcinoma

Gynecologic Oncology

Volumn 104, Issue 1, 2007, Pages 217-221

  Honkavuori, M ^a   Talvensaari Mattila, A ^a   Soini, Y ^a   Turpeenniemi Hujanen, T ^a   Santala, M ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

CA 125; Endometrial cancer; MMP 2; MMP 9; Prognosis

Indexed keywords

CA 125 ANTIGEN; GELATINASE A; GELATINASE B; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE COURSE; ENDOMETRIUM CARCINOMA; FATALITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; CA-125 ANTIGEN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS;

EID: 33846030501     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.08.006     Document Type: Article

References (20)

1. Aglund K., Rauvala M., Puistola U., Ångström T., Turpeenniemi-Hujanen T., Zackrisson B., et al. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol. Oncol. 94 (2004) 699-704
2. Markman M. Hormonal therapy of endometrial cancer. Eur. J. Cancer 41 (2005) 673-675
3. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87 (2005) 287-297
4. Stetler-Stevenson W.G., Hewitt R., and Corcoran M. Matrix metalloproteinases and s invasion: from correlation and causality to the clinic. Cancer Biol. 7 (1996) 147-154
5. Curran S., and Murray G.I. Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol. 189 (1999) 300-308
6. Tryggvason K., Höyhtyä M., and Pyke C. Type IV collagenases in invasive tumours. Breast Cancer Res. Treat. 24 (1994) 209-218
7. Inoue Y., Abe K., Obata K., Yoshioka T., Ohmura G., Doh K., et al. Immunohistochemical studies on matrix metalloproteinase-9 (MMP-9) and type IV collagen in endometrial carcinoma. J. Obstet. Gynaecol. Res. 23 (1997) 139-145
8. Talvensaari-Mattila A., Santala M., Soini Y., and Turpeenniemi-Hujanen T. Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. Anticancer Res. 25 (2005) 4101-4106
9. Väisänen A., Kallioinen M., Taskinen P.J., and Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J. Pathol. 186 (1998) 51-58
10. Väisänen A., Kallioinen M., von Dickhoff K., Laatikainen L., Höyhtyä M., and Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein-a new prognostic marker in uveal melanoma. J. Pathol. 188 (1999) 56-62
11. Vasala K., Pääkkö P., and Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology 62 (2003) 952-957
12. Ruokolainen H., Pääkkö P., and Turpeeniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin. Cancer Res. 10 (2004) 3110-3116
13. Santala M., Simojoki M., Risteli J., Risteli L., and Kauppila A. Type I and type III collagen metabolites as predictors of outcome in epithelial ovarian cancer. Clin. Cancer Res. 5 (1999) 4091-4096
14. Santala M., Talvensaari-Mattila A., and Kauppila A. Peritoneal cytology and preoperative serum CA 125 level are important prognostic indicators of overall survival in advanced endometrial cancer. Anticancer Res. 23 (2003) 3097-3104
15. Santala M., and Talvensaari-Mattila A. DNA ploidy is an independent prognostic indicator of overall survival in stage I endometrial endometrioid carcinoma. Anticancer Res. 23 (2003) 5191-5196
16. Niloff J.M., Klug T.L., Schaetzl E., Zurawski Jr. V.R., Knapp R.C., and Bast Jr. R.C. Elevation of serum CA 125 in carcinomas of the fallopian, endometrium, and end cervix. Am. J. Obstet. Gynecol. 148 (1984) 1057-1058
17. Duk J.M., Aalders J.G., Fleuren G.J., and de Bruijin H.W. CA 125: a useful marker in endometrial carcinoma. Am. J. Obstet. Gynecol. 155 (1986) 1097-1102
18. Patsner B., Mann W.J., Cohen H., and Loesch M. Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma. Am. J. Obstet. Gynecol. 158 (1988) 399-402
19. Sood A.K., Buller R.E., Burger R.A., Dawson J.D., Sorosky J.I., and Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet. Gynecol. 90 (1997) 441-447
20. Moser P.L., Hefler L., Tempfer C., Neunteufel W., Kieback D.G., and Gitsch G. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer. Anticancer Res. 19 (1999) 2365-2367